News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
ad-hoc-news.de Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company's decision to drop the clinical development of its eczema candidate, amlitelimab, for moderate-to-severe atopic dermatitis. Rather than a fundamental breakdown, the move reflects an aggressive R&D pipeline …
Former Sanofi, CVS Health, and McKesson Executive Improve Specialty Drug Access, Affordability and Patient Support NEW YORK, August 06, 2026--(BUSINESS WIRE)--Leap, the healthcare company making specialty medicine more affordable and easier to access, today announced the appointment of Christine Hummel as Senior Vice President …
Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework Improved GAAP Combined R&D and SG&A expense guidance by $10 million at mid-point Sanofi confirmed with Novavax that they are in advanced discussions with regulators regarding …
Antipodes Partners published its "Antipodes Global Strategy" second-quarter 2026 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. The second quarter of 2026 delivered one of the strongest equity market recoveries …
Nurix Therapeutics, Inc. Oral STAT6 degrader advances into clinical development for type 2 inflammatory diseases Nurix has earned approximately $139 million to date under its collaboration with Sanofi and remains eligible to receive approximately $453 million in future milestones associated with the STAT6 program, …
[Sanofi building on New York Ave in Framingham, MA, USA] JHVEPhoto Sanofi (SNY [https://seekingalpha.com/symbol/SNY]) received [https://seekingalpha.com/pr/20605048-press-release-sanofi-s-menquadfi-approved-in-the-eu-for-use-in-infants-from-age-six-weeks] European Commission approval to expand MenQuadfi’s indication to infants aged six weeks and older for protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W …
Rapport financier semestriel 2026 de Sanofi Paris, le 30 juillet 2026. Sanofi annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son rapport financier semestriel au 30 juin 2026. Le rapport financier semestriel peut être …
Key Points Interested in Sanofi? Here are five stocks we like better. Sanofi raised its 2026 outlook after second-quarter sales rose 17.8% to €11.6 billion and business EPS increased 33.3%, driven by Dupixent, new medicines and cost discipline. Dupixent quarterly sales surpassed €5 billion, …
July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea. Shares rose nearly 5% before the bell. Here are the …
(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Thursday sharply lower net profit in its second quarter, while business earnings climbed from last year with strong sales growth. Further, the firm upgraded its fiscal 2026 outlook. For fiscal 2026, the pharmaceutical …
Sanofi Winthrop Industrie Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven …
Key Points Sanofi is growing well, thanks in large part to its drug Dupixent. It has more drugs in development, some of which could turn into big sellers. Its stock is appealingly priced, too.10 stocks we like better than Sanofi › If you've got …
(RTTNews) - Scribe Therapeutics Inc. (SCTX), a clinical-stage biotechnology company, announced pricing of its upsized initial public offering of 8.58 million shares of its common stock at the high end of the range at a public offering price of $15 per share. In addition …
Search by ticker symbol or company name and select a result to open its chart.